Ryan DeMasi

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Roy Fleischmann, Eduardo Mysler, Stephen Hall et al. · The Lancet · 2017 · 496 citations

Medicine, Pharmacology, Pharmacotherapy +12

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

Stanley Cohen, Yoshiya Tanaka, Xavier Mariette et al. · Annals of the Rheumatic Diseases · 2017 · 395 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

J. Wollenhaupt, Eun-Bong Lee, Jeffrey R. Curtis et al. · Arthritis Research & Therapy · 2019 · 320 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15

Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies

Hendrik Schulze‐Koops, Vibeke Strand, Chudy I. Nduaka et al. · Lara D. Veeken · 2016 · 79 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis

Stanley Cohen, Jeffrey R. Curtis, Ryan DeMasi et al. · Rheumatology and Therapy · 2018 · 79 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17